| HOME >> MEDICINE >> TECHNOLOGY |
CAMBRIDGE, Mass., April 29 /PRNewswire-FirstCall/ -- Idenix
Pharmaceuticals, Inc. (Nasdaq: IDIX), a biopharmaceutical company engaged
in the discovery and development of drugs for the treatment of human viral
and other infectious diseases, today reported unaudited financial results
for the first quarter ended March 31, 2008. At March 31, 2008, Idenix's
cash, cash equivalents and marketable securities totaled approximately
$99.0 million.
2008 Year-to-Date Business Highlights
-- Idenix reported positive data from an ongoing phase I/II study of
IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being
developed for the treatment of HIV-1. In the first dosing cohort of
this study, eight HIV-1 infected treatment-naive patients receiving 800
mg of IDX899 once-daily achieved a median reduction in plasma virus
levels of approximately 2.0 log10, or 99 percent, after seven days of
treatment. The 400 mg cohort of this study is now complete and dosing
has been initiated in the 200 mg cohort. To date, no serious adverse
events have been reported and no patients have discontinued from the
study. Data from this clinical trial have been submitted for
presentation at scientific meetings this summer.
-- The company continued to make progress with its hepatitis C discovery
and development programs, having presented data from preclinical
studies of its lead nucleotide prodrug candidate, IDX184, and potential
clinical candidates from its protease inhibitor program at the annual
meeting of the European Association for the Study of the Liver (EASL)
last week. (Please see Idenix press releas
'/>"/>
| SOURCE Idenix Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |